These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 22694113)
1. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer. Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD Am J Manag Care; 2012 May; 18(5):e186-93. PubMed ID: 22694113 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of stereotactic body radiation therapy versus intensity-modulated radiation therapy: an emerging initial radiation treatment option for organ-confined prostate cancer. Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD J Oncol Pract; 2012 May; 8(3 Suppl):e31s-7s. PubMed ID: 22942832 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972 [TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. Yu JB; Cramer LD; Herrin J; Soulos PR; Potosky AL; Gross CP J Clin Oncol; 2014 Apr; 32(12):1195-201. PubMed ID: 24616315 [TBL] [Abstract][Full Text] [Related]
6. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693 [TBL] [Abstract][Full Text] [Related]
7. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. Konski A; Watkins-Bruner D; Feigenberg S; Hanlon A; Kulkarni S; Beck JR; Horwitz EM; Pollack A Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):408-15. PubMed ID: 16887291 [TBL] [Abstract][Full Text] [Related]
8. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Amin NP; Sher DJ; Konski AA Appl Health Econ Health Policy; 2014 Aug; 12(4):391-408. PubMed ID: 25022451 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases. Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China. Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957 [TBL] [Abstract][Full Text] [Related]
11. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed. Carter HE; Martin A; Schofield D; Duchesne G; Haworth A; Hornby C; Sidhom M; Jackson M Radiother Oncol; 2014 Aug; 112(2):187-93. PubMed ID: 24929702 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study. Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer. Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108 [TBL] [Abstract][Full Text] [Related]
14. Spacers in radiotherapy treatment of prostate cancer: is reduction of toxicity cost-effective? Vanneste BG; Pijls-Johannesma M; Van De Voorde L; van Lin EN; van de Beek K; van Loon J; Ramaekers BL; Lambin P Radiother Oncol; 2015 Feb; 114(2):276-81. PubMed ID: 25616537 [TBL] [Abstract][Full Text] [Related]
16. A response to Sher et al, "Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer". Collins SP; Suy S; Chen LN; Collins BT; Dritschilo A Am J Clin Oncol; 2013 Jun; 36(3):316-7. PubMed ID: 23681018 [No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. Zemplényi AT; Kaló Z; Kovács G; Farkas R; Beöthe T; Bányai D; Sebestyén Z; Endrei D; Boncz I; Mangel L Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 26782759 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. Kim H; Vargo JA; Beriwal S; Clump DA; Ohr JP; Ferris RL; Heron DE; Huq MS; Smith KJ Head Neck; 2018 Aug; 40(8):1743-1751. PubMed ID: 29537684 [TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Parthan A; Pruttivarasin N; Davies D; Taylor DC; Pawar V; Bijlani A; Lich KH; Chen RC Front Oncol; 2012; 2():81. PubMed ID: 22934286 [TBL] [Abstract][Full Text] [Related]
20. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? Konski A; Speier W; Hanlon A; Beck JR; Pollack A J Clin Oncol; 2007 Aug; 25(24):3603-8. PubMed ID: 17704408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]